WORLD AIDS DAY: HIV market to grow as single-tablet regimens dominate
This article was originally published in Scrip
On World AIDS Day 2014, Scrip takes a look at the future of the HIV market, and finds that it is set to grow by nearly 40% in the next nine years, driven by the arrival of more single-tablet regimens to rival Bristol-Myers Squibb/Gilead's Atripla (tenofovir disoproxil fumarate/emtricitabine/efavirenz).
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.